InspireMD Begins First U.S. Commercial CGuard Prime TCAR
MIAMI, Florida, USA | November 18, 2026 InspireMD, Inc. has announced the successful completion of the first U.S. commercial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
MIAMI, Florida, USA | November 18, 2026 InspireMD, Inc. has announced the successful completion of the first U.S. commercial...
MIAMI, May 1, 2026 InspireMD, Inc. announced a voluntary U.S. recall of its CGuard® Prime 135 cm carotid stent...
MIAMI, May 1, 2026 InspireMD, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its...
